All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
AACR 2017: Poster 4059/29 – KPC34 for therapy in AML patients
On Tuesday 4th April, at the 107th American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, there was a poster session focused on “Combination Therapies and Approaches to Sensitize Cancer Cells to Drugs”. During this session, a poster (4059/29) titled “KPC34: a co-drug that combines a DNA damaging agent with a targeted therapy for the treatment of AML” by Gregory L. Kucera and colleagues from Wake Forest School of Medicine, North Carolina, was on display.
Standard chemotherapy with Cytarabine (Ara-C) in Acute Myeloid Leukemia (AML) is hindered by chemoresistance which leads to relapse in patients. Chemoresistance can occur due to several mechanisms including reduced activation of Ara-C via down-regulated Deoxycytidine Kinase (dCK) levels or decreased uptake via lowered Equilibrative Nucleoside Transporter 1 (ENT-1) levels. Kucera et al. aimed to assess the efficacy of KPC34, a novel synthetic phospholipid/deoxycytidine analog conjugate, in AML.
The key results were:
- Median survival of KPC34-treated and Ara-C treated mice injected with OCI-AML-3 cells (AML cell line); 44.5 vs 25 days; P = 0.0033
- Retreatment of the KPC34 mice with additional KPC34 resulted in a median survival time of 78.5 days; P = 0.0028
- Median survival in mice treated with KPC34 plus doxorubicin (dox) and Ara-C plus dox; 39 vs 22 days, P = 0.0365
- KPC34 showed a reduction in leukemic burden in the liver and spleen in Patient-Derived Xenograft (PDX) murine model
- Treatment of OCI-AML3 cells with KPC34 led to an inhibition of Protein Kinase C (PKC) signaling
In summary, KPC34 can inhibit PKC and cause DNA termination. The authors concluded by suggesting that KPC34 has the “potential to replace Ara-C-based leukemia treatment regimens as a single agent or in combination” therapy for AML.
References